Mezagitamab (TAK-079) is a fully humanized IgG1lambda monoclonal antibody against CD38 with high affinity for CD38-expressing cells (including plasma mother cells, plasma cells, and natural killer cells), which depletes CD38-expressing tumor cells through antibody- and complement-dependent cytotoxicity Mezagitamab may be used in the study of recurrent/refractory multiple myeloma (RRMM), which is the most common form of cancer. multiple myeloma (RRMM) and primary thrombocytopenic purpura (ITP).
Purity:
97.50%
CAS Number:
[2227490-52-8]
Target:
Apoptosis|||CD38
* VAT and and shipping costs not included. Errors and price changes excepted
